Oxygen Biotherapeutics Sends Letter to Holds, Discusses Progress, Prelim. Results in Trials

Oxygen Biotherapeutics, Inc., (“OBI”) OXBT a developer of oxygen-carrying therapeutics, today announced the Company has issued a Letter to Shareholders. Highlights of the letter include: * Progress in our international Phase IIb clinical trials of Oxycyte® for the treatment of traumatic brain injury, a global market projected to reach $2 billion by 2017 according to GlobalData * Preliminary results from our preclinical trials of Oxycyte® in the U.S., designed to address the FDA's clinical hold * Implementation of our business strategy to focus on the development of Oxycyte® for critical indications while out-licensing non-core indications * Improved cash position resulting from a $5.4 million funding closed in July which provides liquidly to fund projected operating requirements and clinical trials through the remainder of fiscal 2014 * The U.S. Army and U.S. Navy's Cooperative Research & Development Agreements to explore Oxycyte® * Out-licensed Dermacyte® cosmetics line to Valor, which has generated licensing revenues and reduced our operating expenses * Our research partnership with Aurum Biosciences for the development of Oxycyte® for the diagnosis and treatment of stroke, a market projected to grow to $3.6 billion by 2015 according to GlobalData To read the letter in full please visit: http://www.oxybiomed.com/investors.html